Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials

Published:2023-04 Issue: Volume:198 Page:110592
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Yang Qing,Lang Yanlin,Yang Wenjie,Yang Fenghao,Yang Jia,Wu Yucheng,Xiao Xiang,Qin Chunmei,Zou Yutong,Zhao Yuancheng,Kang Deying,Liu Fang

Funder

Health Commission of Sichuan Province

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference52 articles.

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: International Diabetes Federation; 2021.

2. Diabetic kidney disease: a report from an ADA consensus conference;Tuttle;Diabetes Care,2014

3. Diabetic kidney disease;Thomas;Nat Rev Dis Primers,2015

4. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease;de Boer;Kidney Int,2020

5. Unmet need in diabetic nephropathy: failed drugs or trials?;de Zeeuw;Lancet Diabetes Endocrinol,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin: Primus Inter Pares Among Sodium–Glucose Cotransporter-2 Inhibitors?;Journal of Cardiovascular Pharmacology;2024-09

2. Variability of urinary albumin to creatinine ratio and eGFR are independently associated with eGFR slope in Japanese with type 2 diabetes: a three-year, single-center, retrospective cohort study;BMC Nephrology;2024-08-16

3. A study of the visualization of artificial intelligence applications in chronic kidney disease in the literature over the last 20 years;2024-07-11

4. Finerenone: Who should prescribe it for CKD? The physician associate’s perspective;Journal of Nephrology;2024-07-03

5. Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks;Archives of Pharmacy and Pharmaceutical Sciences;2024-05-02